NorthWest Biotherapeutics Inc (NWBO)

[Arby2000]

From the article:

In a recent Phase 3 prospective externally controlled non-randomized trial, the overall survival rate (OS) of GBM patients who received treatment with tumor lysate-loaded DC vaccine (DCVax-L) in addition to the standard of care (SOC) was compared to that of externally matched patients who underwent SOC alone over the same period [68]. The study revealed that the inclusion of DCVax-L along with SOC led to a significant and clinically meaningful extension of survival among GBM patients when compared to contemporaneous, matched external controls who solely received SOC (NCT00045968) [68].